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Abstract
Triglyceride accumulation is associated with obesity and type 2 diabetes. Genetic disruption of diacylglycerol acyltransferase
1 (DGAT1), which catalyzes the final reaction of triglyceride synthesis, confers dramatic resistance to high-fat diet induced
obesity. Hence, DGAT1 is considered a potential therapeutic target for treating obesity and related metabolic disorders.
However, the molecular events shaping the mechanism of action of DGAT1 pharmacological inhibition have not been fully
explored yet. Here, we investigate the metabolic molecular mechanisms induced in response to pharmacological inhibition
of DGAT1 using a recently developed computational systems biology approach, the Causal Reasoning Engine (CRE). The CRE
algorithm utilizes microarray transcriptomic data and causal statements derived from the biomedical literature to infer
upstream molecular events driving these transcriptional changes. The inferred upstream events (also called hypotheses) are
aggregated into biological models using a set of analytical tools that allow for evaluation and integration of the hypotheses
in context of their supporting evidence. In comparison to gene ontology enrichment analysis which pointed to high-level
changes in metabolic processes, the CRE results provide detailed molecular hypotheses to explain the measured
transcriptional changes. CRE analysis of gene expression changes in high fat habituated rats treated with a potent and
selective DGAT1 inhibitor demonstrate that the majority of transcriptomic changes support a metabolic network indicative
of reversal of high fat diet effects that includes a number of molecular hypotheses such as PPARG, HNF4A and SREBPs.
Finally, the CRE-generated molecular hypotheses from DGAT1 inhibitor treated rats were found to capture the major
molecular characteristics of DGAT1 deficient mice, supporting a phenotype of decreased lipid and increased insulin
sensitivity.
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Introduction
Triacylglycerol is a highly efficient energy storage form critical
for surviving periods of starvation and extended physical activity.
Many industrialized societies maintain a diet rich in fat and
carbohydrates, and a sedentary lifestyle leading to the excess
storage of triglyceride in tissues. The resulting adiposity has been
linked to an increased prevalence of multiple diseases such as
diabetes and atherosclerosis [1]. Diacylglycerol Acyltransferase
(DGAT) enzymes catalyze the final step in the synthesis of
triacylglycerol from diacylglycerol (DAG) and fatty acyl-coA
making them attractive targets for reducing triglyceride storage
[2]. Two separate genes encode for the DGAT1 and DGAT2
enzymes [3]. DGAT1 knock out (-/-) mice are lean, resistant to
diet induced obesity and have increased insulin sensitivity, while
the DGAT2 (-/-) genotype is lethal [4,5]. Interestingly, intestine
selective overexpression of DGAT1 in the context of mice null for
DGAT1 reverses the lean phenotype and hepatic steatosis
suggestive that DGAT1 expression in intestine is a major
contributor to metabolic phenotype [6]. Out of a broad panel of
human tissues DGAT1 was most abundant in the small intestine
[2] We have confirmed these findings in human, rat and mouse
tissues with gene chip profiling and RT-qPCR (data not shown).
Therefore we sought to investigate the molecular changes
occurring in the small intestine with pharmacological inhibition
of DGAT1.
Whole genome expression measurements provide snapshots of
the abundance of thousands of transcripts and have the potential
to paint a comprehensive picture of modulated biological processes
in a given sample. While most problems relating to the statistically
robust estimation of transcript levels changing between different
samples have been successfully solved, the task of manually
interpreting the usually hundreds of changing transcript levels is
daunting. At the same time, the amount of biomedical knowledge
is growing rapidly. The PubMed database comprises more than 20
million citations as of October 2010 [7]. Methods that harness this
knowledge for the interpretation of gene expression data are
promising candidates to make the biological interpretation process
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level changes is today.
The most popular class of methods to analyze gene expression
data using pre-defined categories of genes (e.g. pathways,
biological processes) is called gene-set enrichment analysis. Ackermann
& Strimmer give an excellent recent review of the many methods
proposed [8]. Gene-set enrichment methods provide a good first
overview of high-level processes changing between measured
conditions, but oftentimes lack the ability to provide concrete
molecular hypotheses as to the causal drivers of the processes as
well as direct suggestions for experimental follow-up. In this
article, we focus on the use of a novel causal reasoning algorithm
to infer upstream molecular mechanisms that caused observed
expression changes. Causal reasoning algorithms can be viewed as
a form of gene set enrichment with two major enhancements.
First, such methods provide predictions on causal drivers on a
molecular level by using gene sets corresponding to the effects of
defined causal perturbations. Second, they account for direction-
ality of the gene expression changes and hence the directionality of
the inferred upstream molecular causes can be computed as well.
Similar causal reasoning-based approaches have been described in
the work of Pollard et al [9]. Here, we rely on a novel algorithm,
called the Causal Reasoning Engine introduced by Chindelevitch
et al, 2010 [10].
To increase our understanding of a novel DGAT1 inhibitor,
PF-04620110 and its mechanism of action we monitored gene
expression changes in the jejunum of rats following an acute
exposure to PF-04620110. The gene expression changes were used
by the causal reasoning platform to infer the molecular events
shaping the biological response.
Materials and Methods
Ethics Statement
All in vivo procedures were reviewed and approved by the
Institutional Animal Care and Use Committee at Pfizer Inc.
(AUP# 3573).
Animal Experiments
Male Sprague Dawley rats (Charles River Laboratories)
(average initial body weight of approximately 250 grams) were
individually housed in hanging wire mesh cages and acclimated to
a reverse light/dark cycle (lights off at 10:00 am/lights on at 10:00
pm) and high fat Western diet (Research Diets D12079B) for 14
days prior to experimentation. Rats (n=8 per treatment group)
were randomized to receive vehicle or compound PF-04620110 at
3 or 15 mg/kg. PF-04620110 is a highly potent and selective
inhibitor of DGAT1 with an IC50 of 19 nM at human DGAT1
and IC50 of 64 nM at rat DGAT1 [11]. PF-04620110 also
possesses greater than 100-fold selectivity against hDGAT2,
hACAT1, hAWAT1/2, hMGAT2/3, mMGAT1 [11].
Food was removed from each cage 24 hours prior to
administration of DGAT1 inhibitor. Vehicle or test compound
was administered via standard oral gavage in a dose volume of
5 mL/kg and rats were allowed ad libidum access to food and
water for six hours, during which time food intake was monitored.
After six hours animals were sacrificed for blood and tissue
collection. Tissue samples (jejunum, liver) were flash frozen in
liquid nitrogen. Blood was collected via cardiac puncture and
placed into vacutainer EDTA tubes containing Aprotinin and
DPP-IV inhibitor for plasma isolation. Triglyceride concentration
in plasma samples were determined on a Roche 912 clinical
chemistry analyzer (Roche Diagnostics). Plasma samples treated
with Aprotinin and DPP-IV inhibitor were analyzed for total
amide GLP-1 (SPE-MSD), and PYY (SPE-Luminex) according to
manufacturers protocols. Significance P values for food intake,
triglycerides, amide GLP-1 and PYY were calculated using a
student’s unpaired T-test.
Lipomics
Jejunum tissue samples were sent to Tethys Bioscience for
quantitation of lipid metabolites with a proprietary TrueMass
Lipomic Panel. Significance P values were calculated using a
student’s unpaired T-test.
Microarray Gene Expression
Tissue samples were submitted to Genelogic for RNA
purification, probe synthesis and Affymetrix Genechip profiling.
Affymetrix Rat Expression Array 230 2.0 chip was utilized to
assess gene expression. For quality control, RNA degradation plots
were generated for each CEL file. To assess potential RNA
degradation, 39/59 ratios and their associated confidence intervals
were evaluated [12]. Two techniques were used to distill the probe
results into a small number of representative variables; Multidi-
mensional scaling (MDS) [13] and Principal component analysis
(PCA). These two techniques were applied to the data before and
after Robust Mult-Array Average (RMA) [13] signal processing.
During this processing, only the perfect match (PM) probe data
were used; the mismatch (MM) probes were not used.
To assess differential expression of genes between groups of
interest, a common statistical model was applied independently to
each probeset. Gene expression for all sample types was analyzed on
the log2 scale. Linear models were used to calculate t-statistics, which
were subsequently adjusted using the moderated t-statistic procedure
[14]. The Benjamini and Hochberg adjustment procedure [15] based
on controlling the False Discovery Rate (FDR) was used.
TaqMan Quantitative PCR
A subset of the observed gene changes on the Affymetrix array
was confirmed by quantitative PCR analysis (Table S1). First strand
cDNA was synthesized using the Applied Biosystems (ABI) High
Capacity Reverse Transcription Kit according to the manufactur-
er’s protocol. Gene expression was measured using a customized
ABI 384-well TaqMan Low Density Array (TLDA) card and the
TaqMan Universal PCR Master Mix (Applied Biosystems) on an
ABI 7900HT sequence detector. Expression of target genes were
normalized with the house-keeping genes 18S and validated with
ACTB. Expressionlevel of eachgene wascalculatedby RQ method
and expressed as ‘‘relative expression per 10
6 18S’’.
Gene Set Enrichment Analysis (GSEA)
Enrichment analyses were conducted using Gene Ontology
(GO) groupings using a two-sided Fisher’s Exact Test (i.e.
hypergeometric test). The two-sided test can differentiate between
enrichment and depletion of statistically significant results. For
each test, the odds ratio (similar to a fold-change) is calculated
using the observed and expected number of significant genes, as
well as raw p-values. This technique accounts for the size of the
groupings as well as the overlap between related groups in the
hierarchy via conditioning. Each GO terms was scored using
desirability functions [16] where the most desirable GO term
would have large (absolute) fold-change, small p-value and a target
group size of 20 genes.
Causal Reasoning Engine Algorithm
The Causal Reasoning Engine (CRE) follows the general data
model introduced in Pollard et al [9]. We utilized the CRE
Causal Reasoning Network of DGAT1 Inhibition
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statistical measures to assess relevance of uncovered upstream
regulators to plausibly interpret the observed expression changes.
Briefly, the approach relies on a large collection of curated causal
statements of the form:
A½increasesordecreases B,
whereAandBaremeasurablebiologicalentities:
The biological entities can be of different types (e.g. phosphor-
ylated proteins, transcript levels, biological process and compound
exposure) and each statement is tied to accessible, peer-reviewed
articles. For this work, we licensed approximately 450,000 causal
statements from commercial sources (Ingenuity Systems and
Selventa).
Each biological entity in the network and its assumed mode of
regulation is a potential hypothesis (e.g. predicted decrease in PPARG
transcription activity). For each hypothesis, we can now compare all
possible downstream transcriptional changes in the knowledge base
with the observed transcriptional changes in the experiment. We
considertwometricstoquantifythesignificanceofa hypothesis with
respect to our experimental data set, namely enrichment and
correctness. The Enrichment p-value for a hypothesis h quantifies the
statistical significance of finding (#incorrect + #correct) transcripts
within the set of all transcripts downstream of h. The exact p-value
can be computed by a Fisher’s exact test. This is a standard
approach in gene set enrichment methods and does not take the
direction of regulation into account [17].
The Correctness p-value is a measure of significance for the score
of a hypothesis h defined as (#correct - #incorrect). As desired, this
score is high, if the number of correct prediction exceeds the
number of incorrect predictions. To ensure statistical significance
under a null model of randomly re-assigning up- and downreg-
ulated transcripts to arbitrary nodes, we compute the distributions
for this score and derive appropriate p-values. Surprisingly, the
distributions can be computed analytically in polynomial time
using combinatorial programming approaches [10]. The Causal
Reasoning Engine is implemented in the statistical programming
language R [18] and uses the igraph package for representation of
the network of causal assertions.
Network Modeling of the CRE Hypotheses
The analysis results are communicated using the Causal
Reasoning Browser (Figure 1), a Java application based on the
open-source biological network viewer Cytoscape [19]. We have
developed a plugin that enables browsing, clustering, merging,
sorting and filtering of upstream hypotheses in conjunction with
the relevant causal networks.
In the CRE browser an overview graph allows users to visualize
hypotheses and examine their network relationships in the context
of the causal relationships obtained from the literature based
knowledgebase. Each edge in the graph is linked to an evidence
statement directly obtained from the original peer reviewed article.
Furthermore, each hypothesis can be expanded into a network
showing all the causal relationships that qualified the hypothesis
based on the gene expression changes from the experiment.
To facilitate the construction of biological networks from the
generated hypotheses several analytical tools were developed.
Figure 1. A screen shot of the cytoscape based causal reasoning engine browser showing the network overview window,
hypothesis table and parameters filter panel.
doi:10.1371/journal.pone.0027009.g001
Causal Reasoning Network of DGAT1 Inhibition
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clustering tool uses cosine similarity metric and an average linkage
method to group related hypotheses together. The average
similarity for clustering can be adjusted by setting a cluster
threshold to reflect the desired extent of similarity. Where 1
indicates hypotheses with identical supporting evidence and 0
indicates dissimilar hypotheses [20].
Once a subset of hypotheses is selected, either manually or using
the clustering tool, similarity statistics are displayed in the browser.
This includes the percent of unique gene expression changes correctly
explained by this subset of hypotheses, overlap and contradictions.
For each selected set of hypotheses a dynamic heatmap, the evidence
matrix, is automatically generated whereby each cell in the heatmap
represents the relationship between each hypothesis and each gene in
thissubset,ifoneexists.Finally,thebrowserenablestheusertomerge
the hypotheses for further investigation of the underlying context,
evidence statement and source literature.
Results
Food Intake and Plasma triglycerides level
In high fat habituated Sprague Dawley rats, mean six hour food
intake was significantly decreased following administration of PF-
04620110 by 40 and 37% at 3 and 15 mg/kg respectively relative to
mean food intake of vehicle controls (Figure 2A). Six hour fed plasma
triglyceride levels were significantly decreased by 53 and 59% at 3
and 15 mg/kg respectively compared to fed plasma triglyceride of
vehicle controls following a single dose of PF-04620110 (Figure 2B).
TotalamideGLP-1andPYYwerealsosignificantlyincreasedinboth
dose groups (Figure 2C and 2D) at six hours.
Gene expression analysis
A single dose of PF-04620110 resulted in 403 and 831 gene
expression changes in the jejunum at 3 and 15 mg/kg,
respectively, using an adjusted p-value ,0.05 and fold change
$1.3. Table S1 confirms a subset of the observed gene changes on
the affymetrix array using quantitative PCR analysis. In contrast,
no significant gene expression changes in the liver with the
exception of one gene at high dose (data not shown). These data
are consistent with the jejunum having the highest expression of
DGAT1 in the Sprague-Dawley rat as evidenced by the ,10-15
fold lower basal level of DGAT1 expression in the liver as
compared to the jejunum (Data not shown).
Gene Set Enrichment Analysis
Tables 1 and 2 show the top 10 most significant GO terms for
the gene expression changes in the jejunum at high and low dose,
Figure 2. Food intake (A), plasma triglycerides (B), total amide
GLP-1 (C) and total PYY (D) in response to a single dose of PF-
04620110. Symbols indicate statistical significance from vehicle with
p-value thresholds of ,0.001 (*), ,0.005 (ˆ), for n=8 rats per treatment
group.
doi:10.1371/journal.pone.0027009.g002
Table 1. GO enrichment analyses for the 15 mg/kg group.
ID Term Raw p-Value Odds Ratio Size
GO:0006637 (BP) acyl-CoA metabolic process , 0.00001 12.838 14
GO:0005777 (CC) peroxisome , 0.00001 4.64 72
GO:0006071 (BP) glycerol metabolic process , 0.00001 16.615 10
GO:0006066 (BP) alcohol metabolic process , 0.00001 3.291 110
GO:0008203 (BP) cholesterol metabolic process 0.0001 4.155 41
GO:0006869 (BP) lipid transport 0.0001 3.404 59
GO:0006631 (BP) fatty acid metabolic process , 0.00001 2.478 126
GO:0019752 (BP) carboxylic acid metabolic process , 0.00001 1.79 455
GO:0045930 (BP) negative regulation of progression through mitotic cell cycle 0.0002 35.548 6
GO:0004430 (MF) 1-phosphatidylinositol 4-kinase activity 0.0002 Inf 4
*The results are sorted by a scoring function that uses the p-value, odds-ratio and the size of the GO terms.
doi:10.1371/journal.pone.0027009.t001
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dose group indicate several metabolic biological processes
involving lipid, fatty acids, glycerol and cholesterol. However, in
the low dose group there was minor indication of metabolic lipid
changes.
Causal Reasoning Engine Inferences and Network
Modeling
Approximately 76% of the gene changes from each dose group
mapped to biological entities in our knowledge base. Using the
filtering functionality we applied the following cutoffs for the CRE
generated hypotheses; correctness p-value ,0.01, enrichment p-
value ,0.01, minimum number of correctly explained gene
expression changes $3, percent correctly explained gene expres-
sion changes $60%. This resulted in a total of 79 and 160
hypotheses for the 3 and 15 mg/kg dose groups, respectively.
The CRE platform is developed with a set of analysis tools that
enable flexible analysis schemes for evaluation of the biological
significance of the hypotheses and integrating them into
biological network models. However, for the purpose of this
article we report the results from an example systematic approach
utilizing some of the analysis tools we developed in the CRE
browser. The basic premise for this approach is to preserve the
context of the supporting evidence and employ it as the main
driver for integrating the hypotheses into biological networks/
models. To achieve this we started by grouping the hypotheses
using the hypothesis clustering tool. We used a cluster threshold
of 0.15 at which we see clustering of hypotheses that are not mere
surrogates of one another. See tables 3 and 4 for examples of the
top ranking largest clusters at cluster threshold 0.3 and 0.15,
respectively. Table 3 shows the top two clusters from the 15 mg/
kg group at cluster threshold 0.3 to be primarily composed of
redundant hypothesis such as decrease in PPARA- and number of
its ligands, and decrease in a number of SREBF family members.
However, in table 4 the largest and highest ranking cluster for the
15 mg/kg group at cluster threshold 0.15 is indicative of
decreased PPAR signaling, decreased lipids (high-fat diet-,
diacylglycerol-, lipid-) increased fatty acid oxidation enzymes
(EHHADH+, HSD17B4+). The second ranking cluster comprises
hypotheses indicative of decreased sterol regulators (SREBFs-,
SCAP-) and cholesterol trafficking (NPC1-), and decreased insulin
resistance (hyperinsulinism-, supported by causal relations from
studies of high fat diet in insulin resistance animal model [21])
and decreased glucose response regulators and glucose dependant
activators of carbohydrate response element (MLX-, MLXIPL-,
Carbohydrate-).
Table 2. GO enrichment analyses for the 3 mg/kg group.
ID Term Raw p-Value Odds Ratio Size
GO:0008191 (MF) metalloendopeptidase inhibitor activity 0.0001 54.027 5
GO:0005604 (CC) basement membrane 0.0001 6.368 28
GO:0006629 (BP) lipid metabolic process 0 1.894 542
GO:0006457 (BP) protein folding 0.0002 0.085 153
GO:0006066 (BP) alcohol metabolic process 0.0002 2.074 257
GO:0005783 (CC) endoplasmic reticulum 0.0006 1.718 466
GO:0016705 (MF) oxidoreductase activity, acting on paired donors, with
incorporation or reduction of molecular oxygen
0.0006 2.713 103
GO:0005885 (CC) Arp2/3 protein complex 0.0007 17.7 7
GO:0005615 (CC) extracellular space 0.0004 1.439 1419
GO:0005730 (CC) nucleolus 0.001 0 94
*The results are sorted by a scoring function that uses the p-value, odds-ratio and the size of the GO terms.
doi:10.1371/journal.pone.0027009.t002
Table 3. Top two clusters for the high dose at cluster threshold 0.3.
Hypothesis Hypothesis Rank Cluster ID Cluster Size Correctness p-value Enrichment p-value Percent Correct
Clofibrate- 1 1 5 6.38E-16 5.99E-22 0.87
PPARA- 6 1 5 2.32E-07 1.59E-34 0.63
Pirinixic acid- 7 1 5 9.09E-09 1.23E-19 0.76
Gemfibrozil- 33 1 5 6.34E-07 1.98E-10 0.85
Fenofibrate- 45 1 5 0.001993 3.38E-13 0.67
SREBF1- 12 12 5 1.28E-08 1.16E-12 0.86
Srebf1a- 19 12 5 2.55E-07 2.65E-10 0.88
Srebf1c- 60 12 5 0.0002758 2.32E-05 0.89
SREBF2- 76 12 5 0.0036389 3.36E-07 0.75
SCAP- 76 12 5 0.0013972 1.73E-06 0.8
The sign following the hypothesis name indicates the CRE predicted directionality (+ = predicted increase and - = predicted decrease).
doi:10.1371/journal.pone.0027009.t003
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investigate the nature of the causal relationships supporting them
by referring to their original studies. This is especially helpful for
molecular hypotheses with a broad range of context dependant
biological functions such as PPARG- (Rank=5, Correctness p-
value=1.94E-7, Enrichment p-value=1.21E-26). For example,
investigating the causal relationships from the PPARG- subnetwork
(Figure 3) reveals that ,50% of the supporting assertions
consistent with the predicted directionality were derived from
studies on induction of adipogenesis [22,23], the majority of which
in context of adipogenic steatosis due to PPARG overexpression
[24]. On the other hand, many of the assertions inconsistent with
the predicted directionality originated from studies of PPARG
insulin sensitization in Zucker diabetic rat model [25] and
cholesterol efflux in macrophages [26].
Lastly, we constructed biological networks primarily guided by
hypothesis clustering and investigation of the underlying evidence
and the potential inter-hypothesis causal relations from the causal
graph overview. These biological models (summarized in Figure 4)
support 3 major effects of PF-04620110; reversal of the high fat
diet and decreased hyperlipidemia, decreased insulin resistance
and decreased glucose, and altered fatty acid metabolism. The key
high-fat diet responsive regulators supported by the causal
evidence are PPARG- (see above) and SREBFs- (e.g. some of the
assertions supporting SREBF1- are obtained from a study
demonstrating its role in mediating the hyperlipidemic response
to high fat diet [27]). Glucose metabolism is represented by a
network of hypotheses indicative of decreased glucose levels,
decreased glucose response activators and decreased insulin
resistance. The glucose metabolism network appears to be
secondary to decreased lipids; however, there exists causal
interactions with several lipid network components positively
reinforcing both networks as evidenced by edges from the
overview graph and investigating the context of overlapping
Table 4. Top two clusters for the high dose at cluster threshold 0.15 after excluding redundancies.
Hypothesis Hypothesis Rank Cluster ID Cluster Size
Correctness
p-value
Enrichment
p-value
Percent
Correct
PPARA- 6 1 30 2.32E-07 1.59E-34 0.63
MEHP- (PPARG modulator) 10 1 30 2.26E-10 5.24E-13 0.91
PPARGC1A- 11 1 30 1.32E-08 8.94E-09 0.89
FOXA2- 15 1 30 4.25E-07 1.21E-11 0.82
PPARD- 27 1 30 1.46E-07 9.46E-17 0.74
ESRRA- 45 1 30 0.0022058 2.06E-12 0.68
high-fat diet- 45 1 30 0.0011581 1.74E-14 0.67
EHHADH+ 60 1 30 3.51E-08 5.59E-08 1
HSD17B4+ 60 1 30 3.51E-08 5.59E-08 1
9-cis-retinoic acid- 76 1 30 0.0062967 7.64E-06 0.75
PCK1+ 76 1 30 3.30E-09 4.54E-09 1
LPL- 115 1 30 0.0009964 1.61E-06 0.78
meldonium- 115 1 30 8.68E-07 1.17E-06 1
SCD+ 115 1 30 0.0001995 5.89E-06 0.86
quercetin- 164 1 30 0.0006924 0.0025397 1
TFAM- 164 1 30 0.0006092 0.0013388 1
Prasterone- 164 1 30 0.0003124 0.0004421 1
diacylglycerol- 246 1 30 0.0003967 0.0004851 1
lipid- 246 1 30 0.0046444 5.29E-05 0.8
SREBF1- 12 12 15 1.28E-08 1.16E-12 0.86
RXRA- 19 12 15 8.69E-08 3.42E-13 0.79
MLX- 19 12 15 3.86E-10 1.10E-09 1
25-hydroxycholesterol+ 76 12 15 2.35E-05 1.05E-06 0.88
SREBF2- 76 12 15 0.0036389 3.36E-07 0.75
SCAP- 76 12 15 0.0013972 1.73E-06 0.8
hyperinsulinism- 164 12 15 0.0001294 0.0003134 1
essential fatty acid-deficient diet- 164 12 15 1.94E-05 2.50E-05 1
NPC1- 246 12 15 0.0003757 0.0019058 1
MLXIPL- 246 12 15 0.0006679 0.0008302 1
cafeteria diet- 246 12 15 0.0012353 0.0026628 1
carbohydrate- 246 12 15 0.0059513 0.0090411 1
THRSP- 246 12 15 0.0003967 0.0004851 1
The sign following the hypothesis name indicates the CRE predicted directionality (+ = predicted increase and - = predicted decrease).
doi:10.1371/journal.pone.0027009.t004
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third network indicates decrease in some fatty acids like linolenic
and oleic acid but increase in arachidonic acid. Lipomics analysis
of corresponding jejunum tissue from the same rats confirmed the
predicted changes in these free fatty acids. Figure 6 shows the
depletion of oleic acid C18:1n9 and the enrichment of arachidonic
acid C20:4n6 in the jejunum with DGAT1 inhibition. The less
abundant linolenic acid was also significantly depleted -2.4 fold
(umol/g tissue) for both dose groups. Finally, there is also support
for a number of nuclear receptors and co-regulators to cooperate
Figure 4. Summary overview graph showing the biological model constructed for reversal of high fat diet, decreased insulin
resistance and changes in fatty acid metabolism in response to PF-04620110 treatment. (Blue nodes = predicted decrease, Yellow
nodes = predicted increase).
doi:10.1371/journal.pone.0027009.g004
Figure 3. Causal network shows the experimental gene expression changes enriched for the PPARG- hypothesis in the 15 mg/kg
group. 36 genes are consistent with the predicted decreased directionality (bottom), 14 are contradictory (top right) and 6 are ambiguous due to
contradictory literature (top left). (Blue nodes = predicted decrease, Red nodes = observed mRNA decrease, Green nodes = observed mRNA
increase).
doi:10.1371/journal.pone.0027009.g003
Causal Reasoning Network of DGAT1 Inhibition
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and PPARGC1A-).
Discussion
The objective of this study was to employ a novel computational
platform to gain mechanistic insight into the molecular changes
induced by pharmacological inhibition of DGAT1. Acute gene
expression changes were utilized to infer multiple overlapping
molecular regulators of lipid and carbohydrate metabolism
predictive of benefits of DGAT1 inhibition such as lipid lowering
and improved insulin sensitivity. Our analysis allows us to
postulate the molecular network conferring these metabolic
benefits to better understand the mechanism of action for
pharmacological inhibition of DGAT1.
Our understanding of the physiologic role of DGAT1 stems
largely from studies of genetically modified mice that lack DGAT1
from birth. It is noteworthy that this analysis focused on
transcriptomics in the jejunum elicited by the administration of
a pharmacological inhibitor of DGAT1 in an adult rat which
suggests similar molecular phenotype to DGAT1 knockout mice.
Recently, DGAT1 knockout mice were shown to have decreased
expression of PPARalpha, gamma and delta as well as target genes
suggestive of reduced lipid uptake and metabolism and increase
glucose uptake [28] which is consistent with our top ranking
hypotheses. Additionally, DGAT-1 deficient mice demonstrate
resistance to weight gain on high fat diet, improved insulin
sensitivity and a lower percentage of oleic acid in their skeletal
muscle and adipose tissue triglyceride [29]. Again, our CRE
generated hypotheses identified reversal of high fat diet, reduced
insulin resistance and decreased oleic acid. These data support the
notion that the intestine is an important tissue involved in whole
body insulin sensitivity diet-induced obesity. Insulin resistance in
the intestine has been associated with increased apolipoproteins,
chylomicrons, de novo lipogenesis, and increased fatty acid and
cholesterol uptake via CD36 and SCARB1 [30]. In our study not
only was triglyceride synthesis decreased via inhibition of the
target, but transcription of the key apolipoproteins for chylomi-
cron synthesis (ApoB, ApoA I, ApoA IV, and ApoC III) were
reduced. Of these Apo CIII was the most dramatic (see Table S1)
with greater that a 5 fold reduced expression at the high dose. The
expression and secretion of ApoC III is increased in insulin
resistant states and plasma circulating levels are higher in
metabolic syndrome and type II diabetes [31]. Finally, Lee et al
demonstrated that intestine specific expression of DGAT1 in the
DGAT1 deficient mice prevented the knockout mouse from being
resistant to diet induced obesity [6].
In contrast, DGAT1 knockout mice are hyperphagic [29,32];
whereas, administration of PF-04620110 results in a decrease in
food intake. Our working hypothesis is that elevated levels of
Figure 5. Merged causal graph showing potential positive reinforcing interactions between glucose- and SREBF1- supported by
evidence from studies on its role in mediating hyperlipidemia in response to high fat diet [27]. (Blue nodes = predicted decrease, Red
nodes = observed mRNA decrease, Green nodes = observed mRNA increase).
doi:10.1371/journal.pone.0027009.g005
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YY (PYY) are at least in part mediating this response (Figure 2). It
is our belief that decreased food intake is an integral part of the
mechanism of action driving a metabolically favorable profile
following pharmacological inhibition of DGAT1 and thereby did
not try to dissociate food intake dependent effects from food intake
independent effect in our analysis. Normal lipid absorption entails
the breakdown of dietary triglyceride into free fatty acids and 2-
monoacylglycerol by pancreatic lipases in the lumen of the small
intestine. This allows transport of the free fatty acids into the
enterocytes where they can be re-esterified and packaged into
chylomicrons for delivery to the circulation. Clearly the major role
of DGAT1 in triglyceride synthesis and intestinal lipid absorption
has been demonstrated [33] with DGAT1 accounting for 89% of
triglyceride synthesis in rat intestinal membranes. Theoretically,
DGAT1 inhibition would cause an immediate build up of its
substrates, diacylglycerol and free fatty acids. Polyunsaturated fatty
acids have been demonstrated to decrease the expression of
lipogenic genes via SREBP promoter elements (SRE) [34].
Therefore DGAT1 inhibition would result in decreased lipogenesis
in the intestine driven by an excess of free fatty acids. There has
been mounting evidence in high fat diet rodent models and
humans supporting a negative impact of de novo lipogenesis and
monounsaturated fatty acid synthesis on insulin sensitivity
[21,35,36]. Mice fed high fat western diet for one week
demonstrate a robust increase in the expression of intestinal
SREBF1 and SCD-1, and develop insulin resistance with little
change in hepatic gene expression [21,35,36]. Coincidentally,
SREBF1 and SCD1 where robustly down regulated in the
jejunum but unchanged in the liver with DGAT1 inhibition.
Furthermore CRE hypotheses for reduced SREBF1, PPARa,
RXR, MLX, and PGC1a all suggest a decrease in fatty acid
synthesis, while the decrease in SCD1 may be contributing to the
depletion of oleic acid, and secondary enrichment in arachidonic
acid (Figure 6). Recent evidence has indicated a benefit for a high
ratio of C20-C22 PUFAS to saturated and monounsaturated fatty
acids for improved glycemic control and insulin sensitivity [37].
Thus an additional effect of DGAT1 inhibition would be the
insulin sensitizing effect of enriched very long chain PUFA.
The Causal Reasoning approach has the advantage of providing
detailed molecularhypothesesonpotentialcausaldriversofobserved
expression changes. Each assertion can be followed back to the
primary literature providing confidence to the researcher to follow-
up on the computational predictions. In some cases the predicted
direction of the CRE hypothesis may conflict with the observed
direction of thetranscript change. For example, a CREhypothesisof
decreased CFTR protein and/or activity conflicts with the observed
increase in transcripts for CFTR as well as Annexin 2 and S100A10
that complex with CFTR enabling its function [38]. The literature
evidence supporting the CFTR hypothesis came from two studies in
CFTR knockout mice [39,40]. Regulated genes in this context may
include compensatory and/or regulatory feedback gene expression
changes which in turn may complicate the interpretation of some of
the CRE hypotheses. One possibility is that a CRE hypothesis may
represent protein level oractivitywhich isnotnecessarilyreflective of
the mRNA level or that the CRE hypothesis is based on gene
changes in response to an initial decrease in CFTR protein or
activity that led to feedback increase in transcript level hence
reflecting an earlier temporal event. Another example is the CRE
hypotheses for increased fatty acid oxidation enzymes Enoyl-CoA
hydratase (EHHADH), and hydroxysteroid(17-beta) dehydrogenase
4 (HSD17B4). Both of these hypotheses are supported by the same
transcript evidence from a single literature source [41]. Moreover,
the same transcript evidence is completely subsumed under the
much higher ranking hypothesis of decreased PPAR alpha, which
includesdecreased transcriptionofEHHADHand HSD17B4 which
could be an effect of a feedback loop.
Clearly, the hypotheses as well as the resulting model can only
be as good as the underlying causal relationships. Consequently,
the method is unlikely to uncover completely novel areas of
biology. However, it can provide novel insights by reporting
upstream drivers to be relevant in a certain context. As efforts to
curate larger parts of the biomedical literature are underway, we
expect the power of the approach to increase.
We have employed the causal reasoning approach as a means of
visualizing an extensive and diverse set of gene expression changes to
generate high level molecular hypotheses that will enable a better
understanding of the anti-adipogenic and anti-diabetic benefits derived
following pharmacological inhibition of DGAT1. Additionally, this
analysis has allowed us to understand the advantages and limitations of
causal reasoning. The approach has allowed us to confirm in a
systematic fashion that pharmacological inhibition of DGAT1 in adult
rats generates molecular hypotheses that are consistent with the
metabolically beneficial phenotype of mice lacking DGAT1.
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Figure 6. Results from lipomics analysis showing effect of PF-
04620110 on tissue levels of two of the most abundant free
fatty acids: Oleic 18:1n9 and Arachidonic acid 20:4n6 in rat
jejunum. Represented in raw values (umol/g tissue, panel A) and
normalized values (% of total free fatty acids, panel B). Symbols indicate
significance from vehicle with P value thresholds of ,0.001 (*), ,0.005
(ˆ), ,0.01 (,), ,0.05 (+) for n = 8 rats per treatment group.
doi:10.1371/journal.pone.0027009.g006
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